Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
Mi Ran Yun(Yonsei University), Byoung Chul Cho(Yonsei University)
Cited by 60
Related Papers
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
|Annals of Oncology|2023|384
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
|Annals of Oncology|2013|124
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
|Clinical Cancer Research|2020|115